Clin2
NCT06674694Possibly a fitRecruiting

Testing brexpiprazole long-acting shot for schizophrenia

Schizophrenia Disorders

Part of Mental health clinical trials.

This study tests an injectable form of brexpiprazole that stays in the body for a long time. It aims to see if the shot is safe and tolerable for healthy volunteers and people with schizophrenia, and how the body processes it.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
56 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You must be between 18 and 65 years old.
  • You can be a healthy volunteer or have a diagnosis of schizophrenia that has been stable for at least 4 weeks.
  • You must have a body mass index (BMI) between 19 and 26 if healthy, or between 18.5 and 35 if you have schizophrenia.
  • You and your partner must use effective birth control during the study and for one year after the last dose.
  • You cannot have used any other study drugs or devices in the last 28 days.
  • You cannot have certain medical conditions like heart disease, liver or kidney problems, or diabetes that is not well controlled.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07493551Recruiting
Bioequivalence study of a long-acting injection for schizophrenia

This trial tests whether a new version of an extended-release injection is as effective as the original in people with schizophrenia. The study helps ensure patients have access to a reliable treatment option.

Beijing, Beijing Municipality
NCT06561542Recruiting· Phase 1
Safety study of LX22001 injection in healthy adults

This study tests a new injection called LX22001 in healthy volunteers to see how it is processed in the body and if it is safe. It is a first-in-human trial, so you must be in good health and meet specific age, weight, and lifestyle requirements.

Beijing, Beijing Municipality
NCT07742280Not yet recruiting· Phase 2/Phase 3
Extended-release brexpiprazole injection for schizophrenia

This trial tests a new long-acting injection of brexpiprazole, an antipsychotic that may help control schizophrenia symptoms. The study will see how the injection is absorbed, its safety, and how well people tolerate it, potentially offering a longer-lasting treatment option.

NCT05325645Recruiting· Phase 3
Weekly brexpiprazole shot for acute schizophrenia flare-ups

This Phase 3 study tests whether a once-weekly brexpiprazole medicine can help people whose schizophrenia is currently flaring up and who need hospital-level care. It compares care for acute relapse using a longer-lasting (weekly) form of brexpiprazole.

Kure-shi
NCT07547384Not yet recruiting
Aripiprazole Injection Bioequivalence Study for Schizophrenia

This study tests how well a new aripiprazole injection works in your body compared to a standard version. You'll receive injections while your schizophrenia symptoms are stable, and researchers will measure drug levels in your blood to ensure the new version works the same way.

NCT07185815Recruiting· Phase 1/Phase 2
Study of a long-acting cariprazine shot for mood and schizophrenia

This trial tests a monthly injection of cariprazine (a medication for mental health conditions) in people who could benefit from it. It aims to see if the shot is safe, tolerable, and effective compared to taking pills every day.

Ahmedabad

Hear when a new Schizophrenia Disorders trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.